Teva Offers $57.5 Million for BXCL501 Rights, Ties $67.5 Million to IGALMI Path
Key Facts
Teva announced an agreement to acquire rights to assets including the sublingual dexmedetomidine film BXCL501, for $57.5 million in cash at closing, plus conditional payments of up to $67.5 million. According to Bloomberg Law, those payments are tied to milestones related to the supplemental application for IGALMI. The announced terms do not establish that the cash consideration has already been paid; the agreement makes it due at closing. The process began with a preliminary offer from Teva in a court-supervised sale of BioXcel assets, and the company was the stalking-horse bidder in a court-supervised auction. The initial announcement therefore did not confirm that the sale had been completed, while the consideration structure ties part of the deal's value to developments in the supplemental application.
The focus of the regulatory track is the supplemental IGALMI application for home use. The U.S. Food and Drug Administration set November 14, 2026, as its target action date, according to BioXcel. The application concerns treatment of acute agitation associated with schizophrenia or bipolar I or II disorder in adults. The FDA label explains that IGALMI is a sublingual dexmedetomidine film and an alpha-2 adrenergic receptor agonist. The approved indication in the label is for acute treatment under the supervision of a health care provider. The deal's conditional payments are thus tied to milestones for the supplemental application, while the regulatory action date is a defined milestone in that process.
The home-use application is distinct from BioXcel's program for agitation associated with Alzheimer's disease dementia. The company described it as a separate TRANQUILITY program being conducted in a care setting, designed to evaluate the efficacy and safety of a 60-microgram dose of BXCL501 over 12 weeks. This program is unrelated to the ongoing home-use application before the FDA. This distinction means that the home-use regulatory review concerns agitation associated with schizophrenia or bipolar disorder, while dementia remains a separate development program. Distinguishing the tracks avoids conflating the disease groups and treatment settings addressed by the company's plans.
The drug's clinical background in schizophrenia dates to the SERENITY I study, which compared a 120-microgram dose with placebo. After 120 minutes, the PEC score fell by a mean of 8.5 points with the dose, versus 4.8 points with placebo, according to BioXcel's results. The company said the difference between the groups was statistically significant. These results provide a clinical measure of agitation in the study, while the ongoing supplemental application seeks to use IGALMI at home. The study results remain clinical background for the product, while November 14, 2026, is the target action date for the supplemental application.
IGALMI revenue in the first quarter of 2026 was $206,000, compared with $168,000 in the same quarter of 2025, according to BioXcel. This comparison places the drug's commercial performance in the first quarter among the deal's background, alongside payments tied to milestones for the supplemental application. The figures provided do not break down the reasons for the change in revenue, but establish that the product's revenue in the stated period exceeded its level in the corresponding period a year earlier. Teva's closing share price recorded by EL7 was $39.95 on October 26, 2026. This is the available closing price for the session, among the market indicators included in the article.
EL7 published a report on August 28, 2026, about Teva's pursuit of BioXcel assets, ahead of the current announcement of the agreement's terms. That announcement places the deal within Teva's expansion into neuroscience assets, while the next regulatory step remains the FDA's target decision on November 14, 2026, regarding the supplemental IGALMI application for home use. Part of the potential consideration is tied to milestones for that application, while the cash amount is due at closing. On a separate track, the TRANQUILITY program continues to evaluate BXCL501 for agitation associated with dementia in a care setting. The deal thus intersects with two product tracks, each involving a different disease group and development context.